Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds antigen or epitope whose amino acid sequence is...
Reexamination Certificate
2011-08-23
2011-08-23
Belyavskyi, Michail (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds antigen or epitope whose amino acid sequence is...
C424S184100, C424S278100
Reexamination Certificate
active
08003101
ABSTRACT:
The present invention relates to methods of reducing cartilage degradation in a patient comprising administering to a patient in need thereof an effective amount of an antibody antagonist to the mature form of OSM.
REFERENCES:
patent: 5426048 (1995-06-01), Gearing
patent: 5451411 (1995-09-01), Gombotz et al.
patent: 5559012 (1996-09-01), Brailly et al.
patent: 5571513 (1996-11-01), Burstein
patent: 5618715 (1997-04-01), Shoyab et al.
patent: 6706266 (2004-03-01), Life
patent: 0 290 948 (1988-11-01), None
patent: 0 451 612 (1991-10-01), None
patent: 0 485 961 (1992-05-01), None
patent: 0 748 870 (1996-12-01), None
patent: 0 450 742 (1997-05-01), None
patent: 0572 118 (1998-07-01), None
patent: WO 90/12585 (1990-11-01), None
patent: WO 91/09057 (1991-06-01), None
patent: WO 93/05169 (1993-03-01), None
patent: WO 94/04190 (1994-03-01), None
patent: WO 94/05318 (1994-03-01), None
patent: WO 95/00852 (1995-01-01), None
patent: WO 95/09005 (1995-04-01), None
patent: WO 95/13393 (1995-05-01), None
patent: WO 95/33059 (1995-12-01), None
patent: WO 96/09382 (1996-03-01), None
patent: WO 97/16202 (1997-05-01), None
patent: WO 98/18483 (1998-05-01), None
patent: WO 99/48523 (1999-09-01), None
Colman Res. in Immunol. 1994, 145, 33-36.
Ward et al., Therap. Immunol. 1994, 1, 165-171.
U.S. Appl. No. 09/646,727, filed Sep. 21, 2000, Life.
Barton et al., “Oncostatin M stimulates Hep G2 and B9 cells: Possible role in plasmacytoma development” (1994)FASEB Journal8: Abst 2766.
Bell et al., “Oncostatin M induces leukocyte infiltration and cartilage proteoglycan degradation in vivo in goat joints”Arthritis and Rheumatism(1999) 4:2543-1511.
Bonifati et al, “Leukemia inhibitory factor (LIF) and oncostatin M (OSM) hemopoietins, are increased in organ culture supernatant of lesional psoriatic skin”Australas J Dermatol(1999) 38:Abst 2437.
Boutten et al., “Oncostatin M is a potent stimulator of α1-antitrypsin secretion in lung epithelial cells: Modulation by transforming growth factor-β and interferon-y”Am J. Reps Cell&Mol Biol(1998)18:511-520.
Brown et al., “Regulation of MHC expression by oncostatin M”J Cell Biochem(1994) 18:Abstract O 103.
Cai et al., “Oncostatin-M is an autocrine growth factor in Kaposi's sarcoma” Am J Pathol (1994) 145:74-79.
Cao et al., “Oncostatin M inhibits type 1 plasminogen activator inhibitor synthesis in cultured human endothelium” Thrombosis and Haemostatis (1995) 73: Abst 874.
Carrere et al., “The interleukin-1α and oncostatin M co-operation in cartilage degradation requires two proximal AP-1 sites in the MMP-1 promoter”14th European League Against Rheumatism Congress, (1999) Abst 972 Glasgow.
Carroll et al, “Antagonism of the Il-6 cytokine subfamily—a potential strategy for more effective therapy in rheumatoid arthritis”Inflamm Res(1999) 47:1-7.
Cawston et al., “The regulation of MMPs and TIMPs in cartilage turnover” Ann NY Acad Sci (1999) 878:120-129.
Cawston et al., “Interleukin-1 and Oncostatin M in combination promote the release of collagen fragments from bovine nasal cartilage in culture”Biochem Biophys Res Comm(1999) 215:377-385.
Cawston et al., “The role of oncostatin M in animal and human conective tissue collagen turnover and its localization with the rheumatoid joint”Arthritis&Rheumatism(1998) 41:1760-1771.
Cichy et al., “Regulation of the type II oncostatin M receptor expression in lung-derived epithelial cells”FEBS Lett(1998) 429:412-416.
Chauhan et al., “Oncostatin M induces association of GRB2 with janus kinase JAK2 in multiple myeloma cells”Blood(1995) 86:Abst 214.
Cleaver et al., “Interleukin-13 blocks the release of collagen fragments from bovine nasal cartilage treated with interleukin-α and oncostatin M”14thEuropean League Against Rheumatism Congress(1999) Abst 966.
Duncan et al., “Oncostatin M stimulates collagen and glycosaminoglycan production by cultured normal dermal fibroblasts: Insensitivity of sclerodermal and keloidal fibroblasts”J Invest Dermatol(1995)104:128-133.
Ensoli et al., “Inflammatory cytokines and HIV-1-associated neurodegeneration: Oncostatin-M produced by mononuclear cells from HIV-1-infected individuals induces apoptosis of primary neurons”J Immunol(1999)162:6268-6277.
Este et al., “Oncostatin M inhibits HIV-TAT mediated transactivation in HeLa-TAT cells”10thInternational Conference on AIDS(1994) Abst PB0283.
Faris et al “The Oncostatin M response in Kaposi's Sarcoma Cells Involves JAKs, Adaptor Proteins, Raf-1 and MEK-1”FASEB Journal(1995) 9:Abst 1175.
Friend et al., “Interaction of oncostatin-M with both shared and specific receptors defined by structure/function studies”Cytokine(1995) 7:Abst A286.
Gearing et al., “Proliferative responses and binding properties of hematopoietic cells transfected with low-affinity receptors for leukemia inhibitory factor, oncostatin-M, and cillary neurotorphic factor”Proc Natl Acad Sci USA(1994) 91:1119-1123.
Geisterfer et al., “Cytokines oncostatin M and interleukin 1 regulate the expression of the IL-6 receptor (gp80, gpl 130)”Cytokine(1995) 7:503-509.
Grenier et al., “Oncostatin M production and regulation in human polymorphonuclear neutrophils”Cytokine(1997) 9:Abst 129.
Guillen et al., “Oncostatin M down-regulates basal and induced cytochromes P450 in human hepatocytes ”J Pharm Exp Therap(1998) 285:127-134.
Herbert et al., “Effect of ciprofibrate on fibrinogen synthesis in vitro on hepatoma cells and in vivo in genetically obese Zucker rats”Blood Coag Fibrinol(1999) 10:234-244.
Heymann et al., “Human interleukin for DA cells/leukemia inhibitory factor and oncostatin M enhance membrane expression of intercellular adhesion molecule-1 on melanoma cells but not the shedding of its soluble form”Cytokine(1995) 7:111-117.
Heymann et al., “Upmodulation of αvβ1 integrin on human tumor cells by leukemia inhibitory factor (LIF) and oncostatin M(OSM)”Bulletin du Cancer(1995) 83:13-21.
Heymann et al., “Modulation of the expression of αvβ1 integrin on the surface of human cancer cells by leukaemia inhibitory factor (LIF) and oncostatin M (OSM)”Bulletin du Cancer(1995) 83:13-21.
Hui et al., “Transforming growth factor-β1 blocks the release of collagen fragments from bovine nasal cartilage stimulated by interleukin-1α in combination with oncostatin M”4thEuropean League Against Rheumatism Congress(1999)Abst 973.
Ichihara et al., “Murine oncostatin M transduces signals only through its specific receptor but not through LIF receptor/GP130 complex”Exp Hematol(1995) 23:Abst 364.
Ichihara et al., “Oncostatin M and leukemia inhibitory factor do not use the same functional receptor in mice”Blood(1997) 90:165-173.
Komine et al., “Th-1 and Th-2 lymphocytes differently regtulated epidermal keratin gene expression”J Invest Dermatol(1995) 104:Abst 190.
Koshy et al., “The interleukin-1a in combination with oncostatin M promoted the breakdown of human articular cartilage”14thEuropean League Against Rheumatism Congress(1999) Abst 970.
Lewis et al., “Leukemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF) and Oncostatin M (OSM) actuate P21 ras in neuroblastoma cell line”Society for Neuroscience(1993) 19:Abst 540.3.
Li et al., “Effect of delivery route on pulmonary response to oncostatin M”Annual Meeting of the American Association of Pharmaceutical Scientsts(1999) Abst.
Liu et al., “Oncostatin M activates LDL receptor ene transceiption in sterol repressed liver cells”FASEB Journal(1994) 8:Abstr. 3148.
Liu et al., “Concostatin M inhibits breast cancer cell growth”Proc Amer Assoc Cancer Res(1995) 36:Abst 1529.
Liu et al., “
Life Paul F.
Rees Edward S.
Rhodes Andrew D.
Belyavskyi Michail
Fedon Jason C.
GlaxoSmithKline LLC
Han William T.
LandOfFree
Inflammatory mediator antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inflammatory mediator antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inflammatory mediator antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2645755